Age-related Macular Degeneration (AMD) is one of the leading causes of vision loss in Australians over 50 and affects millions worldwide. As research advances quickly, new treatments are continuously improving outcomes for patients living with this condition. At Queensland Eye and Retina Specialists in Brisbane, Dr Sean Cheng, Dr James Sax, Dr Andrew Dorman and the team are at the forefront of delivering cutting-edge care. This blog examines the latest treatment developments for 2025 and 2026, and their implications for patients with AMD.

Understanding Age-related Macular Degeneration
AMD primarily affects the macula, the central part of the retina responsible for the sharp, detailed vision needed for reading, driving, and recognising faces. There are two main types:
- Dry AMD: Caused by gradual thinning of the macula and a buildup of deposits called drusen. These drusen lead to progressive RPE dysfunction and photoreceptor death. This form of AMD progresses slowly but can cause significant vision impairment over time.
- Wet AMD: This is less common but is responsible for more severe vision loss, and involves abnormal blood vessel growth under the retina that can leak fluid and blood, causing rapid vision loss.
Early detection is crucial, and Queensland Eye and Retina Specialists can provide comprehensive screening for at risk patients.
What’s New in AMD Treatment for 2025 and 2026?
Advances and growth in medical research have brought new treatments and technologies looking to help improve patient outcomes:
- Extended-Interval Anti-VEGF Therapies
Traditional anti-vascular endothelial growth factor (anti-VEGF) injections require frequent visits. Newer formulations of anti-VEGF therapies such as aflibercept 8mg (Eyhea HD) allow for longer intervals between injections without compromising effectiveness, helping to reduce treatment burden and improving quality of life. - Novel Anti-VEGF Agents
Newer anti-VEGF agents have recently been approved for use. Faricimab (Vabysmo) is a bispecific antibody which targets VEGF-A and Ang-2, providing longer durability and potentially reduced treatment frequency. It also provides an option for those not responsive to traditional Anti-VEGF medications. - Novel Drug Delivery Systems
Internationally there are trials underway of implantable devices that provide continuous drug release over a period of time, usually months. These injectables enable sustained treatment of wet AMD with fewer interventions. - Medication Approved for Geographic Atrophy
A new medication, pegcetacoplan (Syfovre), has been approved by the TGA for the treatment of Geographic Atrophy. Until now this condition has had no available treatment, and although this is not a cure, the intravitreal injection has been shown to potentially slow disease progression.
Traditional Treatments Remain Vital
While emerging therapies may offer new treatment options, current treatments continue to be highly effective:
- Anti-VEGF Injections: The mainstay for wet AMD, these injections aim to reduce abnormal blood vessel growth and leakage.
- Nutritional Supplements: For dry AMD, certain vitamin and mineral supplements may slow progression, when taken as recommended.
- Low Vision Aids: Devices and rehabilitation can help patients maximise remaining vision.
The Role of Queensland Eye and Retina Specialists
Under the expert care of Dr Sean Cheng and the team at QERS, patients in Brisbane and Townsville have access to the latest diagnostic tools and treatments for AMD. The team stays updated with international research to provide personalised care plans that optimise vision preservation and quality of life.
Cost and Accessibility
Our team at Queensland Eye and Retina Specialists, in Brisbane, is available to discuss cost-related questions and Medicare rebates for advanced AMD treatments.
If you or a loved one has AMD, consult Queensland Eye and Retina Specialists in Brisbane or in Townsville to discuss the latest treatments available. Early intervention and expert care can make all the difference in preserving your vision.